# Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria

Study · id `cardio:ct-nct01230034` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01230034](<https://clinicaltrials.gov/study/NCT01230034>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01230034

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 206 participants.

## Technical summary

Registry record NCT01230034. Randomized; no masking; primary purpose treatment. Start 2010-10 (registry gives no type); primary completion 2011-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 206 participants (planned count; ClinicalTrials.gov record NCT01230034, source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)
- Start date: 2010-10 (registry gives no type) (ClinicalTrials.gov record NCT01230034, source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)
- Primary completion: 2011-06 (anticipated) (ClinicalTrials.gov record NCT01230034, source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)
- Completion: 2011-07 (anticipated) (ClinicalTrials.gov record NCT01230034, source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT01230034, source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01230034-2010-10-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
- Condition: Hypertension
- Condition: Type 2 Diabetes Mellitus
- Condition: Microalbuminuria
- Intervention (Drug): Ramipril
- Intervention (Drug): Imidapril
- Lead sponsor: University of Pavia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Ramipril (`cardio:ramipril`)
- Registry lists this organization as the lead sponsor: University of Pavia (`cardio:org-university-of-pavia`)

## Provenance

Content hash: 119c3801bc76e6d44405e7ce475b36d27fd41890b735d12eb8d844edcf899bd6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
